Positive Results in Phase 2a Trial

by webmaster

Shares of Pliant Therapeutics experienced a notable surge following the announcement that its lead product candidate, bexotegrast, successfully met both primary and secondary endpoints in a clinical trial.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Significant Market Growth

With a 30% increase, the stock rose to $18.91 in premarket trading on Tuesday. This positive development comes as a relief to investors, as the shares had previously fallen by 25% year-to-date at the close of Monday’s market.

Promising Clinical Trial Results

Pliant Therapeutics, a clinical-stage biopharmaceutical company, conducted a Phase 2a trial to assess the effectiveness of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis.

During the 12-week treatment period, bexotegrast demonstrated excellent tolerability among patients. According to Pliant, plasma concentrations saw a notable increase with dose.

The trial showcased encouraging results at the initial three doses that were tested. Bexotegrast exhibited a reduction in enhanced liver fibrosis scores and PRO-C3 levels compared to a placebo at week 12.

Furthermore, the patients experienced stabilization of liver chemistry, including a promising dose-dependent trend in the reduction of alkaline phosphatase levels relative to a placebo at week 12.

Overall, these findings indicate great potential for bexotegrast as a treatment option for primary sclerosing cholangitis and suspected moderate to severe liver fibrosis.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Related Articles

Leave a Comment

+ 14 = 23